Ryvu Therapeutics S.A. (RVU.WA)
PLN 36.5
(-3.95%)
PLN 36.5
(-3.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.73 Million PLN | -94.91% |
| 2022 | 93.07 Million PLN | 22.5% |
| 2021 | 75.97 Million PLN | 78.53% |
| 2020 | 42.55 Million PLN | 953.15% |
| 2019 | -4.98 Million PLN | -108.16% |
| 2018 | 61.14 Million PLN | 24.24% |
| 2017 | 49.21 Million PLN | 27.99% |
| 2016 | 38.45 Million PLN | 59.86% |
| 2015 | 24.05 Million PLN | 73.17% |
| 2014 | 13.89 Million PLN | 49.74% |
| 2013 | 9.27 Million PLN | -6.82% |
| 2012 | 9.95 Million PLN | -21.27% |
| 2011 | 12.64 Million PLN | 42.31% |
| 2010 | 8.88 Million PLN | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.1 Million PLN | -30.59% |
| 2024 Q2 | 44.96 Million PLN | 4618.95% |
| 2023 Q2 | 36.7 Million PLN | 47.31% |
| 2023 Q1 | 24.91 Million PLN | 28.26% |
| 2023 FY | 4.73 Million PLN | -94.91% |
| 2023 Q4 | 1.58 Million PLN | -95.35% |
| 2023 Q3 | 34.15 Million PLN | -6.96% |
| 2022 Q3 | 24.48 Million PLN | -6.14% |
| 2022 Q1 | 22.94 Million PLN | 1.72% |
| 2022 Q2 | 26.08 Million PLN | 13.68% |
| 2022 FY | 93.07 Million PLN | 22.5% |
| 2022 Q4 | 19.42 Million PLN | -20.65% |
| 2021 Q4 | 22.56 Million PLN | 9.3% |
| 2021 Q1 | 11.62 Million PLN | 11.63% |
| 2021 FY | 75.97 Million PLN | 78.53% |
| 2021 Q2 | 21.08 Million PLN | 81.47% |
| 2021 Q3 | 20.63 Million PLN | -2.13% |
| 2020 Q4 | 10.41 Million PLN | -1.39% |
| 2020 FY | 42.55 Million PLN | 953.15% |
| 2020 Q1 | 10.79 Million PLN | 136.6% |
| 2020 Q2 | 10.92 Million PLN | 1.19% |
| 2020 Q3 | 10.55 Million PLN | -3.32% |
| 2019 Q1 | 19.32 Million PLN | -5.28% |
| 2019 Q4 | -29.48 Million PLN | -405.68% |
| 2019 FY | -4.98 Million PLN | -108.16% |
| 2019 Q3 | 9.64 Million PLN | -57.05% |
| 2019 Q2 | 22.45 Million PLN | 16.23% |
| 2018 Q3 | 14.77 Million PLN | 9.99% |
| 2018 Q4 | 20.4 Million PLN | 38.05% |
| 2018 FY | 61.14 Million PLN | 24.24% |
| 2018 Q2 | 13.43 Million PLN | 6.88% |
| 2018 Q1 | 12.57 Million PLN | -11.5% |
| 2017 FY | 49.21 Million PLN | 27.99% |
| 2017 Q3 | 11.48 Million PLN | -47.18% |
| 2017 Q1 | 1.77 Million PLN | -80.91% |
| 2017 Q2 | 21.74 Million PLN | 1124.67% |
| 2017 Q4 | 14.2 Million PLN | 23.63% |
| 2016 Q1 | 10.63 Million PLN | -5.1% |
| 2016 FY | 38.45 Million PLN | 59.86% |
| 2016 Q4 | 9.3 Million PLN | -7.64% |
| 2016 Q3 | 10.07 Million PLN | 19.32% |
| 2016 Q2 | 8.44 Million PLN | -20.63% |
| 2015 Q4 | 11.2 Million PLN | 104.5% |
| 2015 Q3 | 5.48 Million PLN | 60.92% |
| 2015 Q2 | 3.4 Million PLN | -14.0% |
| 2015 Q1 | 3.96 Million PLN | -7.82% |
| 2015 FY | 24.05 Million PLN | 73.17% |
| 2014 Q1 | 2.53 Million PLN | -4.84% |
| 2014 Q4 | 4.29 Million PLN | 14.1% |
| 2014 Q3 | 3.76 Million PLN | 14.44% |
| 2014 Q2 | 3.29 Million PLN | 29.57% |
| 2014 FY | 13.89 Million PLN | 49.74% |
| 2013 Q4 | 2.66 Million PLN | 12.74% |
| 2013 FY | 9.27 Million PLN | -6.82% |
| 2013 Q1 | -3.26 Million PLN | -232.63% |
| 2013 Q2 | -4.62 Million PLN | -41.85% |
| 2013 Q3 | 2.36 Million PLN | 151.17% |
| 2012 Q3 | 2.33 Million PLN | 157.78% |
| 2012 FY | 9.95 Million PLN | -21.27% |
| 2012 Q2 | -4.04 Million PLN | -11.23% |
| 2012 Q1 | -3.63 Million PLN | 0.0% |
| 2012 Q4 | 2.45 Million PLN | 5.17% |
| 2011 FY | 12.64 Million PLN | 42.31% |
| 2010 FY | 8.88 Million PLN | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioceltix S.A. | 15.38 Million PLN | 69.203% |
| BIOTON S.A. | 57.55 Million PLN | 91.768% |
| Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 94.071% |
| Mabion S.A. | 59.52 Million PLN | 92.04% |
| Molecure S.A. | 31.73 Million PLN | 85.068% |
| NanoGroup S.A. | 7.82 Million PLN | 39.463% |
| Pharmena S.A. | -32.76 Million PLN | 114.461% |
| Poltreg S.A. | 15.47 Million PLN | 69.383% |
| Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 83.743% |
| Synthaverse S.A. | 26.35 Million PLN | 82.022% |
| Urteste S.A. | 5.96 Million PLN | 20.61% |